Cytokine removal in human septic shock: Where are we and where are we going?

Abstract

Although improving, the mortality from septic shock still remains high despite increased international awareness. As a consequence, much effort has focused on alternative treatment strategies in an effort to improve outcomes. The application of blood purification therapies to improve immune homeostasis has been suggested as one such method, but these approaches, such as high-volume continuous haemofiltration or cytokine and/or endotoxin removal, have enjoyed little success to date. More recently, the use of sorbent technologies has attracted much attention. These adsorbers are highly effective at removing inflammatory mediators, in particular, cytokines, from the bloodstream. This narrative review is the executive summary of meetings held throughout the 6th International Fluid Academy Days in Antwerp, Belgium (Nov 23-25, 2017), focusing on the current understanding regarding the use of such adsorbers in humans with septic shock. We followed a modified Delphi approach involving a combination of evidence appraisal together with expert opinion in order to achieve recommendations for practice and, importantly, future research.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 91

1. 1.

   Rhee C, Dantes R, Epstein L, CDC prevention epicenter program, et al. Incidence and trends of sepsis in US Hospitals using clinical vs claims data, 2009–2014. JAMA. 2017;318:1241-1249.

   Not in our library10.1001/jama.2017.13836

2. 2.
   The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis · 2014

   No notice
3. 3.

   Stoller J, Halpin L, Weis M, et al. Epidemiology of severe sepsis: 2008–2012. J Crit Care. 2016;31(1):58-62.

   Not in our library10.1016/j.jcrc.2015.09.034

4. 4.

   Machado FR, Cavalcanti AB, Bozza FA, SPREAD Investigators; Latin American Sepsis Institute Network, et al. The epidemiology of sepsis in Brazilian intensive care units (the Sepsis PREvalence Assessment Database, SPREAD): an observational study. Lancet Infect Dis. 2017;17:1180-1189.

   Not in our library10.1016/s1473-3099(17)30322-5

5. 5.

   Shankar-Hari M, Ambler M, Mahalingasivam V, Jones A, Rowan K, Rubenfeld GD. Evidence for a causal link between sepsis and long-term mortality: a systematic review of epidemiologic studies. Crit Care. 2016;20:101.

   Not in our library10.1186/s13054-016-1276-7

6. 6.

   Harrison AM, Gajic O, Pickering BW, Herasevich V. Development and implementation of sepsis alert systems. Clin Chest Med. 2016;37:219-229.

   Not in our library10.1016/j.ccm.2016.01.004

7. 7.

   Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013;41:1167-1174.

   Not in our library10.1097/ccm.0b013e31827c09f8

8. 8.

   Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA. 2014;311:1308-1316.

   Not in our library10.1001/jama.2014.2637

9. 9.

   Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840-851.

   Not in our library10.1056/nejmra1208623

10. 10.

    Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862-874.

    Not in our library10.1038/nri3552

11. 11.

    Iskander KN, Osuchowski MF, Stearns-Kurosawa DJ, et al. Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev. 2013;93:1247-1288.

    Not in our library10.1152/physrev.00037.2012

12. 12.

    Dreiher J, Almog Y, Sprung CL, SEPSIS-ISR Group, et al. Temporal trends in patient characteristics and survival of intensive care admissions with sepsis: a multicenter analysis. Crit Care Med. 2012;40(3):855-860.

    Not in our library10.1097/ccm.0b013e318236f7b8

13. 13.

    Kadri SS, Rhee C, Strich JR, et al. Estimating ten-year trends in septic shock incidence and mortality in United States academic medical centers using clinical data. Chest. 2017;151:278-285.

    Not in our library10.1016/j.chest.2016.07.010

14. 14.

    Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey A. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med. 2014;42:625-631.

    Not in our library10.1097/ccm.0000000000000026

15. 15.

    Iwashyna TJ, Cooke CR, Wunsch H, Kahn JM. Population burden of long-term survivorship after severe sepsis in older Americans. J Am Geriatr Soc. 2012;60:1070-1077.

    Not in our library10.1111/j.1532-5415.2012.03989.x

16. 16.

    Torio CM, Andrews RM. National inpatient hospital costs: the most expensive conditions by payer, 2011: statistical brief #160 Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD); 2006.

    Not in our library

17. 17.

    Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165-228.

    Not in our library10.1007/s00134-012-2769-8

18. 18.

    Zhou F, Peng Z, Murugan R, Kellum JA. Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med. 2013;41:2209-2220.

    Not in our library10.1097/ccm.0b013e31828cf412

19. 19.

    Callard R, George AJ, Stark J. Cytokines, chaos, and complexity. Immunity. 1999;11:507-513.

    Not in our library10.1016/s1074-7613(00)80125-9

20. 20.

    Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801-810.

    Not in our library10.1001/jama.2016.0287

21. 21.

    Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs. 2003;27(9):792-801.

    Not in our library10.1046/j.1525-1594.2003.07289.x

22. 22.

    van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017;17(7):407-420.

    Not in our library10.1038/nri.2017.36

23. 23.

    Honoré PM, Matson JR. Extracorporeal removal for sepsis: acting at the tissue level–the beginning of a new era for this treatment modality in septic shock. Crit Care Med. 2004;32(3):896-897.

    Not in our library10.1097/01.ccm.0000115262.31804.46

24. 24.

    Di Carlo JV, Alexander SR. Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis. Int J Artif Organs. 2005;28:777-786.

    Not in our library10.1177/039139880502800803

25. 25.

    Peng ZY, Bishop JV, Wen XY, et al. Modulation of chemokine gradients by apheresis redirects leukocyte trafficking to different compartments during sepsis, studies in a rat model. Crit Care. 2014;18:R141.

    Not in our library10.1186/cc13969

26. 26.

    Lukaszewicz AC, Payen D. Purification methods: a way to treat severe acute inflammation related to sepsis? Crit Care. 2013;17:159.

    Not in our library10.1186/cc12757

27. 27.

    Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P. High-volume haemofiltration in human septic shock. Intensive Care Med. 2001;27:978-986.

    Not in our library10.1007/s001340100963

28. 28.

    Honore PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med. 2000;28:3581-3587.

    Not in our library10.1097/00003246-200011000-00001

29. 29.

    Joannes-Boyau O, Honore PM, Perez P, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med. 2013;39:1535-1546.

    Not in our library10.1007/s00134-013-2967-z

30. 30.

    Clark E, Molnar AO, Joannes-Boyau O, Honore PM, Sikora L, Bagshaw SM. High-volume hemofiltration for septic acute kidney injury: a systematic review and meta-analysis. Crit Care. 2014;18:R7.

    Not in our library10.1186/cc13184

31. 31.

    Cavaillon JM, Munoz C, Fitting C, Misset B, Carlet J. Circulating cytokines: the tip of the iceberg? Circ Shock. 1992;38(2):145-152.

    Not in our library

32. 32.
    Mitochondrial DAMPs Increase Endothelial Permeability through Neutrophil Dependent and Independent Pathways · 2013

    No notice
33. 33.

    Vincent JL, Laterre PF, Cohen J, et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock. 2005;23:400-405.

    Not in our library10.1097/01.shk.0000159930.87737.8a

34. 34.

    Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301:2445-2452.

    Not in our library10.1001/jama.2009.856

35. 35.

    Payen DM, Guilhot J, Launey Y, ABDOMIX Group, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41:975-984.

    Not in our library10.1007/s00134-015-3751-z

36. 36.

    Coudroy R, Payen D, Launey Y, ABDOMIX group, et al. Modulation by polymyxin-B hemoperfusion of inflammatory response related to severe peritonitis. Shock. 2017;47:93.

    Not in our library10.1097/shk.0000000000000725

37. 37.

    Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA. 2018;320(14):1455-1463.

    Not in our library10.1001/jama.2018.14618

38. 38.
    Is polymyxin B-immobilized fiber column ineffective for septic shock? A discussion on the press release for EUPHRATES trial · 2017

    Not checked
39. 39.

    Chang T, Tu Y-K, Lee C-T, et al. Effects of polymyxin B hemoperfusion on mortality in patients with severe sepsis and septic shock: a systemic review, meta-analysis update, and disease severity subgroup meta-analysis. Crit Care Med. 2017;45:e858-e864.

    Not in our library10.1097/ccm.0000000000002362

40. 40.

    Payen D. Haemoperfusion with polymyxin B membrane: recent results for an old debate! Anaesth Crit Care Pain Med. 2019;38(1):3-4.

    Not in our library10.1016/j.accpm.2018.12.010

41. 41.

    Pickkers P, Russell JA. Treatment with a polymyxin B filter to capture endotoxin in sepsis patients: is there a signal for therapeutic efficacy? Intensive Care Med. 2019;45(2):282-283.

    Not in our library10.1007/s00134-018-5481-5

42. 42.

    Duchesne JC, Kaplan LJ, Balogh ZJ, Malbrain MNLG. Role of permissive hypotension, hypertonic resuscitation and the global increased permeability syndrome in patients with severe haemorrhage: adjuncts to damage control resuscitation to prevent intra-abdominal hypertension. Anaesthesiol Intensive Ther. 2015;47:143-155.

    Not in our library10.5603/ait.a2014.0052

43. 43.
    Principles of fluid management and stewardship in septic shock: it is time to consider the four D’s and the four phases of fluid therapy · 2018

    No notice
44. 44.
    Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb® sorbent porous polymer beads · 2018

    No notice
45. 45.

    Malbrain ML, Marik PE, Witters I, et al. Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. Anaesthesiol Intensive Ther. 2014;46(5):361-380.

    Not in our library10.5603/ait.2014.0060

46. 46.

    Kobe Y, Oda S, Matsuda K, Nakamura M, Hirasawa H. Direct hemoperfusion with a cytokine-adsorbing device for the treatment of persistent or severe hypercytokinemia: a pilot study. Blood Purif. 2007;25:446-453.

    Not in our library10.1159/000111568

47. 47.

    Pfortmueller CA, Meisel C, Fux M, Schefold JC. Assessment of immune organ dysfunction in critical illness: utility of innate immune response markers. Intensive Care Med Exp. 2017;5:49.

    Not in our library10.1186/s40635-017-0163-0

48. 48.

    Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13:260-268.

    Not in our library10.1016/s1473-3099(13)70001-x

49. 49.

    Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med. 2008;14:64-78.

    Not in our library10.2119/2007-00102.monneret

50. 50.

    Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306:2594-2605.

    Not in our library10.1001/jama.2011.1829

51. 51.

    Schefold JC. Measurement of monocytic HLA-DR (mHLA-DR) expression in patients with severe sepsis and septic shock: assessment of immune organ failure. Intensive Care Med. 2010;36:1810-1812.

    Not in our library10.1007/s00134-010-1965-7

52. 52.

    Leentjens J, Kox M, Koch RM, et al. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am J Respir Crit Care Med. 2012;186:838-845.

    Not in our library10.1164/rccm.201204-0645oc

53. 53.

    Drewry AM, Ablordeppey EA, Murray ET, et al. Comparison of monocyte human leukocyte antigen-DR expression and stimulated tumor necrosis factor alpha production as outcome predictors in severe sepsis: a prospective observational study. Crit Care. 2016;20:334.

    Not in our library10.1186/s13054-016-1505-0

54. 54.

    Quinto BM, Iizuka IJ, Monte JC, et al. TNF-α depuration is a predictor of mortality in critically ill patients under continuous veno-venous hemodiafiltration treatment. Cytokine. 2015;71(2):255-260.

    Not in our library10.1016/j.cyto.2014.10.024

55. 55.

    Van Snick J. Interleukin-6: an overview. Annu Rev Immunol. 1990;8:253-278.

    Not in our library10.1146/annurev.iy.08.040190.001345

56. 56.

    Venet F, Lukaszewicz AC, Payen D, Hotchkiss R, Monneret G. Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr Opin Immunol. 2013;25:477-483.

    Not in our library10.1016/j.coi.2013.05.006

57. 57.

    Monneret G, Finck ME, Venet F, et al. The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett. 2004;95:193-198.

    Not in our library10.1016/j.imlet.2004.07.009

58. 58.

    Frencken JF, van Vught LA, Peelen LM, et al. An unbalanced inflammatory cytokine response is not associated with mortality following sepsis: a prospective cohort study. Crit Care Med. 2017;45:e493-e499.

    Not in our library10.1097/ccm.0000000000002292

59. 59.

    Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the genetic and inflammatory markers of sepsis (GenIMS) study. Arch Intern Med. 2007;167:1655-1663.

    Not in our library10.1001/archinte.167.15.1655

60. 60.

    De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De Sutter JH, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol. 1999;10:846-853.

    Not in our library10.1681/asn.v104846

61. 61.

    Kellum JA, Song M, Venkataraman R. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med. 2004;32:801-805.

    Not in our library10.1097/01.ccm.0000114997.39857.69

62. 62.

    Namas RA, Namas R, Lagoa C, et al. Hemoadsorption reprograms inflammation in experimental gram-negative septic peritonitis: insights from in vivo and in silico studies. Mol Med. 2012;18:1366-1374.

    Not in our library10.2119/molmed.2012.00106

63. 63.

    Peng ZY, Carter MJ, Kellum JA. Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med. 2008;36:1573-1577.

    Not in our library10.1097/ccm.0b013e318170b9a7

64. 64.

    Peng ZY, Wang HZ, Carter MJ, et al. Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis. Kidney Int. 2012;81:363-369.

    Not in our library10.1038/ki.2011.320

65. 65.

    Kellum JA, Venkataraman R, Powner D, Elder M, Hergenroeder G, Carter M. Feasibility study of cytokine removal by hemoadsorption in brain-dead humans. Crit Care Med. 2008;36:268-272.

    Not in our library10.1097/01.ccm.0000291646.34815.bb

66. 66.

    Poli EC, Alberio L, Bauer-Doerries A, Marcucci C, Roumy A, Kirsch M, et al. Cytokine clearance with CytoSorb® during cardiac surgery: a pilot randomized controlled trial. Crit Care. 2019;23(1):108.

    Not in our library10.1186/s13054-019-2399-4

67. 67.

    Sathe PSP, Kumar S, Choudhary S. Clinical experience of using a novel extracorporeal cytokine adsorption column for treatment of septic shock with multiorgan failure. Crit Care (London, England). 2015;19(Suppl 1):P130.

    Not in our library10.1186/cc14210

68. 68.

    Honoré Patrick M, Matson James R. Critical Care. 2002;6(5):394.

    Not in our library10.1186/cc1826

69. 69.

    Matson J, Zydney A, Honoré PM. Blood filtration: new opportunities and the implications of systems biology. Crit Care Resusc. 2004;6:209-217.

    Not in our library

70. 70.

    DA Laddomada T, Balicco B. Case series of patients with severe sepsis and septic shock treated with a new extracorporeal sorbent. Crit care (London, England). 2016;20:P193.

    Not in our library10.1186/s13054-016-1372-8

71. 71.
    Hemoadsorption by CytoSorb in septic patients: a case series · 2017

    No notice
72. 72.

    Friesecke S, Stecher SS, Gross S, Felix SB, Nierhaus A. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J Artif Organs. 2017;20:252-259.

    Not in our library10.1007/s10047-017-0967-4

73. 73.

    Schädler D, Porzelius C, Jörres A, et al. A multicenter randomized controlled study of an extracorporeal cytokine hemoadsorption device in septic patients. Crit Care. 2013;17(Suppl 2):P62.

    Not in our library

74. 74.
    The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial · 2017

    No notice
75. 75.

    Friesecke S, Träger K, Schittek GA, et al. International registry on the use of the CytoSorb® adsorber in ICU patients: study protocol and preliminary results. Med Klin Intensivmed Notfmed. 2017.

    Not in our library10.1007/s00063-017-0342-5

76. 76.
    Effect of hemoadsorption during cardiopulmonary bypass surgery – a blinded, randomized, controlled pilot study using a novel adsorbent · 2016

    No notice
77. 77.

    Nemeth E, Kovacs E, Racz K, et al. Impact of intraoperative cytokine adsorption on outcome of patients undergoing orthotopic heart transplantation—an observational study. Clin Transpl. 2018.

    Not in our library10.1111/ctr.13211

78. 78.

    Öveges N, Hawchar F, László I, et al. Early cytokine adsorption in septic shock (ACESS-trial): results of a proof concept, pilot study. Crit Care. 2018;22(Suppl 1):82.

    Not in our library10.1016/j.jcrc.2018.11.003

79. 79.

    Hawchar F, Lazlo I, Oveges N, Trasy D, Molnar Z. Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study. J Crit Care. 2018.

    Not in our library10.1016/j.jcrc.2018.11.003

80. 80.

    Bellani G, Laffey JG, Pham T, LUNG SAFE Investigators; ESICM Trials Group, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788-800.

    Not in our library10.1001/jama.2016.0291

81. 81.

    Umbrello M, Formenti P, Bolgiaghi LU, Chiumello D. Current concepts of ARDS: a narrative review. Int J Mol Sci. 2017;18:64.

    Not in our library10.3390/ijms18010064

82. 82.

    Martin TR. Lung cytokines and ARDS: Roger S Mitchell lecture. Chest. 1999;116(1 Suppl):2S-8S.

    Not in our library10.1378/chest.116.suppl_1.2s

83. 83.

    Peek GJ, Mugford M, Tiruvoipati R. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009;374:1351-1363.

    Not in our library10.1016/s0140-6736(09)61069-2

84. 84.

    Lees NJ, Rosenberg A, Hurtado-Doce AI, et al. Combination of ECMO and cytokine adsorption therapy for severe sepsis with cardiogenic shock and ARDS due to Panton-Valentine leucocidin-positive Staphylococcus aureus pneumonia and H1N1. J Artif Organs. 2016;19(4):399-402.

    Not in our library10.1007/s10047-016-0915-8

85. 85.

    Traeger K, Schuetz C, Fischer G, et al. Cytokine reduction in the setting of an ARDS-associated inflammatory response with multiple organ failure. In: Case reports in critical care.

    Not in our library10.1155/2016/9852073

86. 86.

    Bruenger F, Kizner L, Weile J, Morshuis M, Gummert JF. First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report. Int J Artif Organs. 2015;30:113-116.

    Not in our library10.5301/ijao.5000382

87. 87.

    Becze Z, Molnar Z, Fazakas J. Can procalcitonin levels indicate the need for adjunctive therapy in sepsis? Int J Antimicrob Agents. 2015;46(Suppl 1):S13-S18.

    Not in our library10.1016/j.ijantimicag.2015.11.002

88. 88.

    Pupelis G, Drozdova N, Mukans M, Malbrain ML. Serum procalcitonin is a sensitive marker for septic shock and mortality in secondary peritonitis. Inflammation. 2014;37(1):223-234.

    Not in our library10.1007/s10753-013-9733-9

89. 89.

    Trásy D, Tánczos K, Németh M, EProK study group, et al. Early procalcitonin kinetics and appropriateness of empirical antimicrobial therapy in critically ill patients: a prospective observational study. J Crit Care. 2016;34:50-55.

    Not in our library10.1016/j.jcrc.2016.04.007

90. 90.

    Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26:1793-1800.

    Not in our library10.1097/00003246-199811000-00016

91. 91.

    Poli Elettra Camille, Simoni Chiara, André Pascal, Buclin Thierry, Longchamp David, Perez Marie-Hélène, Ferry Thomas, Schneider Antoine Guillaume. Clindamycin clearance during Cytosorb® hemoadsorption: A case report and pharmacokinetic study. The International Journal of Artificial Organs. 2019;42(5):258-262.

    Not in our library10.1177/0391398819831303

Cited by papers we hold 6

• The use of a hemoperfusion column that removes endotoxin and cytokines in the complex therapy of widespread peritonitis complicated by septic shock · 2022
  Not checked
• Release mechanisms of major DAMPs · 2021
  No notice
• Targeting Cytokines, Pathogen-Associated Molecular Patterns, and Damage-Associated Molecular Patterns in Sepsis via Blood Purification · 2021
  No notice
• Immunopathogenesis and treatment of cytokine storm in COVID-19 · 2021
  No notice
• COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup · 2020
  Corrected
• Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: A randomized crossover double-blind study · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.